Order intake and net sales grew strongly in Q2 2026, with EBITA up 19% and margins improving across most business areas. Nine acquisitions in H1 2026 boosted growth, especially in Life Science, while the financial position remains robust despite increased net debt.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.